Summit's primary objective has been realized. That objective was to enable Dr. Loring's and Dr. Bratt-Leal's autologous dopamine neuron replacement therapy for Parkinson's disease research project to move from bench to bedside as effectively and quickly as possible. We clearly know that Parkinson's disease (PD) is a progressive disease and understand that time passing is a critical concern for those with PD.
(Please watch our video to better understand why we support autologous dopamine neuron replacement therapy for Parkinson's disease.)
We successfully supported and promoted this brilliant body of science to the point where it was noticed by a for-profit organization with the needed funding. The iPSC-based therapy has been transferred to the for-profit organization and is now on an accelerated path to FDA-approval to begin clinical trials. Summit will continue to provide progress reports to our subscribers through our newsletter.
Summit's secondary goal is now coming into focus. It is our intention to provide support for those receiving the therapy.
Our efforts continue with a passionate dedication to create increasing awareness, education and support evidence-based regenerative medical research for persons with Parkinson's disease. Please join our efforts towards regenerative medicine becoming a reality in mainstream medicine for the millions suffering from Parkinson's and, eventually, other neurological conditions.
Summit for Stem Cell Foundation is a non-profit, 501(c)(3) volunteer organization and is dependent on charitable contributions.
Please help. Donate today.
We thank you.